These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33551724)

  • 1. PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?
    Menniti FS; Chappie TA; Schmidt CJ
    Front Neurosci; 2020; 14():600178. PubMed ID: 33551724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
    Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
    Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.
    Suzuki K; Kimura H
    CNS Neurosci Ther; 2018 Jul; 24(7):604-614. PubMed ID: 29318783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32.
    Polito M; Guiot E; Gangarossa G; Longueville S; Doulazmi M; Valjent E; Hervé D; Girault JA; Paupardin-Tritsch D; Castro LR; Vincent P
    eNeuro; 2015; 2(4):. PubMed ID: 26465004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
    D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
    J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
    Suzuki K; Harada A; Suzuki H; Capuani C; Ugolini A; Corsi M; Kimura H
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
    Hsu YT; Liao G; Bi X; Oka T; Tamura S; Baudry M
    Neuropharmacology; 2011 Dec; 61(8):1275-81. PubMed ID: 21816164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.
    Uthayathas S; Masilamoni GJ; Shaffer CL; Schmidt CJ; Menniti FS; Papa SM
    Neuropharmacology; 2014 Feb; 77():257-67. PubMed ID: 24490227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.
    Harada A; Kaushal N; Suzuki K; Nakatani A; Bobkov K; Vekich JA; Doyle JP; Kimura H
    Int J Neuropsychopharmacol; 2020 Feb; 23(2):96-107. PubMed ID: 31689714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways.
    Megens AA; Hendrickx HM; Mahieu MM; Wellens AL; de Boer P; Vanhoof G
    Pharmacol Res Perspect; 2014 Aug; 2(4):e00057. PubMed ID: 25505601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
    Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
    Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
    Amin HS; Parikh PK; Ghate MD
    Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic deletion of PDE10A selectively impairs incentive salience attribution and decreases medium spiny neuron excitability.
    Piccart E; De Backer JF; Gall D; Lambot L; Raes A; Vanhoof G; Schiffmann S; D'Hooge R
    Behav Brain Res; 2014 Jul; 268():48-54. PubMed ID: 24698799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
    Chappie T; Humphrey J; Menniti F; Schmidt C
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy.
    Li YW; Seager MA; Wojcik T; Heman K; Molski TF; Fernandes A; Langdon S; Pendri A; Gerritz S; Tian Y; Hong Y; Gallagher L; Merritt JR; Zhang C; Westphal R; Zaczek R; Macor JE; Bronson JJ; Lodge NJ
    Neuropharmacology; 2016 Mar; 102():121-35. PubMed ID: 26522433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia.
    Charych EI; Jiang LX; Lo F; Sullivan K; Brandon NJ
    J Neurosci; 2010 Jul; 30(27):9027-37. PubMed ID: 20610737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.
    Wilson JM; Ogden AM; Loomis S; Gilmour G; Baucum AJ; Belecky-Adams TL; Merchant KM
    Neuropharmacology; 2015 Dec; 99():379-86. PubMed ID: 26256420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.